buy rate reect view see bia upsid
number next month enough posit news ow
clinic market keep investor enthus total address
market nextgen sequenc today posit updat
ci medic polici multigen genet test panel support view
post posit updat posit multigen genet test panel
weekend updat eectiv today rather deni coverag
multigen genet test panel larg power nextgen sequenc
technolog consid panel medic necessari perform
contract lab medic necess criteria met least one gene
panel chang expand reimburs genet test panel
perform custom interestingli among reason cite
chang new polici facilit patient access clinic trial
anoth proof point see payer increas willing pay
test could enhanc access clinic trial someth histor
consid research domain
expect diagnost becom increasingli import stori
beyond
polici chang consist previous express view
trend newsow diagnost busi continu improv
front implic medicar recent draft
coverag determin nextgen sequenc oncolog mix see
backdoor regul challeng view least encourag
medicar extend comment period jan dec-end previous
comment amass date see comment
critic respons improv view albeit slightli
viabl path forward medicar reimburs lab develop tumor prole
test power nextgen sequenc could near term event
diagnost newsow mostli nois outlook larg
novaseq-cycl depend think diagnost becom critic part
stori
up estim reect strong result guidanc price target
increas forecast reect strong result
guidanc announc last week increas price target
price jan usd
price target reect
enterpris valu use project level
debt cash
ttm revenu forecast increas
multipl turn previou
valuat multipl multipl
slight discount averag forward
revenu multipl
believ
compar period today character
revenu upsid enthusiasm
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
previous assum sustain current revenu multipl
assumpt seem reason world see upsid
downsid number
forecast ratio
period end expens net incom attribut non-control incom attribut dilut share share alreadi ex amort cash flowoper cash cash ep incl
period end asset equival st receiv expens current current equip intang asset asset liabil account portion long-term current debt less current long-term liabil stockhold januari
